This article presents a dual-stock valuation exercise centered on Qantas Airways (QAN) and ResMed (RMD), positioning both as potential 2026 growth candidates. The framing as "growth investments" suggests the analyst expects outperformance relative to historical earnings, though the piece lacks catalyst specificity or near-term catalysts to support elevation to institutional-grade newsflow.
For QAN, the aviation sector context matters: post-pandemic normalization in domestic and international travel, fuel price exposure, and labor cost pressures remain structural headwinds. Any valuation uplift depends on capacity discipline and pricing power in an increasingly competitive market. The industrial cyclical exposure creates sensitivity to economic slowdown risks.
RMD operates in medical devices and cloud software, a more secular growth profile than airlines. The company benefits from aging demographics and digital health adoption, but valuation multiples remain pressured by rising interest rates and competition from established players and startups alike. ResMed's earnings quality and recurring revenue streams offer defensive characteristics unusual for growth sectors.
Sector implication: This pairing reflects asset-class diversification rather than a coherent thematic trade. The lack of forward guidance, earnings surprises, or material corporate actions limits market-moving potential. Retail investor interest may follow analyst upgrades, but institutional positioning likely remains conditional on broader macro and sector-specific triggers.